Organisation paid for research Program year 2025 Source: CMS Open Payments

Cenexel Atlanta

Neither a doctor nor a teaching hospital

Research payments

$6,402,724

12 payments

Through program year 2025, Cenexel Atlanta is reported as receiving $6,402,724 in research payments, across 12 payments.

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$6,402,724	12

Breakdown

Who paid Research payments · program year 2025

E.R. Squibb & Sons, L.L.C. $6,346,024 11 payments
Novartis Pharmaceuticals Corporation $56,700 1 payment

Studies the money was for Research payments · program year 2025

A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants with DSM-5 Schizophrenia $4,911,562 1 payment
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $556,921 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $299,385 1 payment
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $289,114 1 payment
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $231,034 1 payment
A Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Trial to Investigate Efficacy and Safety of Intravenous Mij821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects W $56,700 1 payment
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $20,307 1 payment
An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia $17,173 1 payment
An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia $11,852 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $6,492 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.